JNJ 54175446

Drug Profile

JNJ 54175446

Alternative Names: JNJ-54175446

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen-Cilag
  • Class Antidepressants; Azoles; Phenols; Pyridines; Pyrimidines
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in Belgium (PO, Suspension)
  • 14 Nov 2017 Janssen-Cilag International completes a phase I trial in Healthy volunteers in Belgium (PO) (NCT03088644)
  • 02 Jun 2017 Janssen Research & Development completes a phase I trial in Major depressive disorder in Germany and the Netherlands (PO) (NCT02902601)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top